Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00110916 | Treatment for Patients With Osteoarthritis (OA) of the Knee | PHASE2 | COMPLETED | 165 | — | — | Jun 1, 2004 | Feb 1, 2005 | Feb 22, 2008 | - | — |
| Arm | Type | Description |
|---|---|---|
| Anakinra | EXPERIMENTAL | anakinra |
| placebo | PLACEBO_COMPARATOR | placebo |
| Name | Type | Description |
|---|---|---|
| Intra-articular metHuIL-1ra (anakinra) | DRUG | anakinra |
| placebo | DRUG | placebo |
Inclusion Criteria: - Diagnosed with knee OA as determined by American College of Rheumatology (ACR) criteria - Pain defined by a level of greater than 30 mm on a 100 mm Visual Analogue Scale (VAS) - No evidence of active effusion or inflammatory flare, confirmed by investigator - Must exhibit radio...